SCHEMBL5446149

SCHEMBL5446149

NC(=O)c1c(NC(=O)Nc2ccccc2)sc2c1CCC(O)C2

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 1/20 0.74
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
EPHB4 P54760 1/20 0.55
MAPT P10636 4/20 0.55
ALDH1A1 P00352 3/20 0.55
GAA P10253 2/20 0.55
LMNA P02545 1/20 0.55
PTPN1 P18031 1/20 0.54
TP53 P04637 1/20 0.52
DUSP3 P51452 1/20 0.51
PTPN5 P54829 1/20 0.51
PTPN11 Q06124 1/20 0.51
KDM4E B2RXH2 1/20 0.51
THRB P10828 1/20 0.51
PDE4B Q07343 3/20 0.50
PDE4D Q08499 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5752965 1.00 TNIK (0.74) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5459994 1.00 TNIK (0.74) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5451267 0.89 TNIK (0.59) TNIKNPC1RAB9AMAPTALDH1A1
SCHEMBL5453345 0.89 TNIK (0.59) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5448399 0.89 TNIK (0.62) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5446191 0.86 TNIK (0.59) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5453529 0.86 TNIK (0.59) TNIKMAPTDUSP3PTPN5PTPN11
SCHEMBL5451415 0.86 TNIK (0.56) TNIKMEN1KMT2ANPC1RAB9A
SCHEMBL5459133 0.86 TNIK (0.59) TNIKMEN1KMT2AMAPTLMNA
SCHEMBL5458879 0.85 TNIK (0.58) TNIKMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 TNIK 4134/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.